TickerStat.comEloxx Pharmaceuticals annual book value per share
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Book Value Per Share Growth & History (ELOX)
Eloxx Pharmaceuticals's book value per share was -$27.35 for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$27.35 | $48.41 | — |
| 2024 | 2024-12-31 | -$75.75 | $3.34 | — |
| 2023 | 2023-12-31 | -$79.09 | -$24.97 | — |
| 2022 | 2022-12-31 | -$54.13 | -$167.79 | — |
| 2021 | 2021-12-31 | $113.66 | $1.57 | +1.40% |
| 2020 | 2020-12-31 | $112.09 | -$285.95 | −71.84% |
| 2019 | 2019-12-31 | $398.04 | -$128.48 | −24.40% |
| 2018 | 2018-12-31 | $526.51 | $185.08 | +54.21% |
| 2017 · Dec 31 | 2017-12-31 | $341.43 | $285.56 | +511.09% |
| 2017 · Jun 30 | 2017-06-30 | $13.13 | -$84.78 | −86.59% |
| 2016 · Dec 31 | 2016-12-31 | $55.87 | $42.02 | +303.28% |
| 2016 · Jun 30 | 2016-06-30 | $97.90 | -$188.93 | −65.87% |
| 2015 · Dec 31 | 2015-12-31 | $13.85 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $286.83 | -$586.72 | −67.16% |
| 2014 | 2014-06-30 | $873.56 | $140.36 | +19.14% |
| 2013 | 2013-06-30 | $733.20 | -$881.18 | −54.58% |
| 2012 | 2012-06-30 | $1,614.38 | -$941.48 | −36.84% |
| 2011 | 2011-06-30 | $2,555.86 | -$9,506.29 | −78.81% |
| 2010 | 2010-06-30 | $12,062.15 | — | — |
Eloxx Pharmaceuticals quarterly book value per share
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.50 | — | — |
| Q1 2026 | 2026-03-31 | -$16.45 | — | — |
| Q4 2025 | 2025-12-31 | -$27.35 | $48.41 | — |
| Q4 2024 | 2024-12-31 | -$75.75 | $3.34 | — |
| Q4 2023 | 2023-12-31 | -$79.09 | -$24.97 | — |
| Q3 2023 | 2023-09-30 | -$101.80 | -$76.50 | — |
| Q2 2023 | 2023-06-30 | -$94.42 | -$103.62 | — |
| Q1 2023 | 2023-03-31 | $82.73 | $23.39 | +39.42% |
| Q4 2022 | 2022-12-31 | -$54.13 | -$167.79 | — |
| Q3 2022 | 2022-09-30 | -$25.30 | -$193.63 | — |
| Q2 2022 | 2022-06-30 | $9.20 | -$198.25 | −95.57% |
| Q1 2022 | 2022-03-31 | $59.34 | $29.25 | +97.21% |
| Q4 2021 | 2021-12-31 | $113.66 | $1.57 | +1.40% |
| Q3 2021 | 2021-09-30 | $168.33 | $3.10 | +1.87% |
| Q2 2021 | 2021-06-30 | $207.45 | -$14.99 | −6.74% |
| Q1 2021 | 2021-03-31 | $30.09 | -$257.84 | −89.55% |
| Q4 2020 | 2020-12-31 | $112.09 | -$285.95 | −71.84% |
| Q3 2020 | 2020-09-30 | $165.24 | -$332.55 | −66.81% |
| Q2 2020 | 2020-06-30 | $222.45 | -$386.31 | −63.46% |
| Q1 2020 | 2020-03-31 | $287.92 | -$133.56 | −31.69% |
| Q4 2019 | 2019-12-31 | $398.04 | -$128.48 | −24.40% |
| Q3 2019 | 2019-09-30 | $497.79 | -$146.79 | −22.77% |
| Q2 2019 | 2019-06-30 | $608.76 | -$147.29 | −19.48% |
| Q1 2019 | 2019-03-31 | $421.48 | $205.62 | +95.26% |
| Q4 2018 | 2018-12-31 | $526.51 | $185.08 | +54.21% |
| Q3 2018 | 2018-09-30 | $644.58 | $616.21 | +2172.27% |
| Q2 2018 | 2018-06-30 | $756.05 | $742.92 | +5659.72% |
| Q1 2018 · Mar 31 | 2018-03-31 | $215.86 | $173.62 | +410.97% |
| Q4 2017 · Dec 31 | 2017-12-31 | $341.43 | $285.56 | +511.09% |
| Q1 2018 · Sep 30 | 2017-09-30 | $28.37 | -$49.47 | −63.55% |
| Q4 2017 · Jun 30 | 2017-06-30 | $13.13 | -$84.78 | −86.59% |
| Q1 2017 · Mar 31 | 2017-03-31 | $42.25 | -$79.32 | −65.25% |
| Q4 2016 · Dec 31 | 2016-12-31 | $55.87 | $42.02 | +303.28% |
| Q1 2017 · Sep 30 | 2016-09-30 | $77.84 | -$192.04 | −71.16% |
| Q4 2016 · Jun 30 | 2016-06-30 | $97.90 | -$188.93 | −65.87% |
| Q1 2016 · Mar 31 | 2016-03-31 | $121.57 | -$231.24 | −65.54% |
| Q4 2015 · Dec 31 | 2015-12-31 | $13.85 | -$364.99 | −96.34% |
| Q1 2016 · Sep 30 | 2015-09-30 | $269.88 | -$442.91 | −62.14% |
| Q4 2015 · Jun 30 | 2015-06-30 | $286.83 | -$586.72 | −67.16% |
| Q3 2015 | 2015-03-31 | $352.81 | -$272.62 | −43.59% |
| Q2 2015 | 2014-12-31 | $378.84 | -$306.38 | −44.71% |
| Q1 2015 | 2014-09-30 | $712.79 | $316.02 | +79.65% |
| Q4 2014 | 2014-06-30 | $873.56 | $140.36 | +19.14% |
| Q3 2014 | 2014-03-31 | $625.43 | -$365.93 | −36.91% |
| Q2 2014 | 2013-12-31 | $685.22 | $90.54 | +15.23% |
| Q1 2014 | 2013-09-30 | $396.77 | -$594.16 | −59.96% |
| Q4 2013 | 2013-06-30 | $733.20 | -$881.18 | −54.58% |
| Q3 2013 | 2013-03-31 | $991.36 | -$1,211.22 | −54.99% |
| Q2 2013 | 2012-12-31 | $594.68 | -$946.97 | −61.43% |
| Q1 2013 | 2012-09-30 | $990.93 | -$1,180.55 | −54.37% |
| Q4 2012 | 2012-06-30 | $1,614.38 | -$941.48 | −36.84% |
| Q3 2012 | 2012-03-31 | $2,202.58 | — | — |
| Q2 2012 | 2011-12-31 | $1,541.65 | — | — |
| Q1 2012 | 2011-09-30 | $2,171.48 | — | — |
| Q4 2011 | 2011-06-30 | $2,555.86 | — | — |
Eloxx Pharmaceuticals book value per share trends
Over the last five fiscal years, Eloxx Pharmaceuticals's book value per share decreased from $112.09 to -$27.35, a change of -$139.43. The latest reported quarter, Q2 2026, shows $11.50.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...